Hamburg said that the drug does not meaningfully reducing
the size of tumors, nor help the patients live longer. The drug was also
exposing patients to serious side effects, such as hemorrhaging and severe high
blood pressure.
As of right now, Avastin will remain on the market as
treatment for other cancers. However, insurers might not continue paying for
the drug which would put it out of reach for post patients, as it costs around
$88,000 a year.
Snyder and Wenner, P.C.
602-224-0005
No comments:
Post a Comment